Z 008
Alternative Names: Z-008Latest Information Update: 29 Apr 2024
At a glance
- Originator Ziphius Vaccines
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Apr 2024 Z 008 is available for licensing as of 17 Apr 2024. https://ziphius.org/pipeline (Ziphius Vaccines pipeline, April 2024)
- 17 Apr 2024 Preclinical trials in Cancer in Belgium (Parenteral) prior to April 2024 (Ziphius Vaccines pipeline, April 2024)